Loading…

Loading grant details…

Active HORIZON European Commission

Storming Immune Monogenic Conditions through Multiomic and Gene Editing Approaches


Funder European Commission
Recipient Organization Fundacio Institut de Recerca Contra la Leucemia Josep Carreras
Country Spain
Start Date Jan 01, 2024
End Date Dec 31, 2027
Duration 1,460 days
Number of Grantees 27
Roles Associated Partner; Participant; Coordinator
Data Source European Commission
Grant ID 101119927
Grant Description

The human immune system controls the efficiency to respond to infections and eliminate aberrant cells, such as cancer cells.

Immune function depends on the balanced contribution of many genes, encoding for receptors, cytokines, cell signalling molecules and transcription factors and are modulated by a wide range of environmental and epigenetic factors.

Monogenic mutations for immune-related genes, also known as Inborn Errors of Immunity (IEI), provide unique examples for understanding immune fitness.

IEI, individually considered as rare diseases, constitute a group of >400 immune disorders with a combined prevalence similar to leukemias (1/1,000-1/5,000).

For a given mutated gene, IEI patients can display a wide range of phenotypic expressivity (from asymptomatic to severely impaired) and different responses to treatments. Therefore, there is an unmet need to address the wide underlying impact of IEI. Previous EU consortia have not addressed these questions in full.

It is therefore needed a new generation of researchers, equipped with a complete set of scientific, technological and strategic skills; and a wide vision to face the outstanding challenges in the IEI field.

To this end, the IMMERGE MSCA DN combines the talent of leaders from different clinical and basic research and biotech environments to train 11 doctoral candidates.

Through our research activity and training activities, we will address key challenges in the field: 1) To assess the functional impact of IEI in different immune cell types through single cell and bulk multiomics. 2) To develop computational tools for dissecting the altered cellular pathways underlying specific IEI. 3) To genetically correct or model IEI and develop pre-clinical models.

With our strategy, IMMERGE will generate an outstanding network of professionals able to develop impactful studies that will change the field, generate tools for personalised medicine and generate awareness in the society and influence policy makers.

All Grantees

Universidad Pompeu Fabra; Epiqmax Gmbh; The Chancellor Masters and Scholars of the University of Cambridge; Genome Research Limited; European Molecular Biology Laboratory; Universitat Basel; Leadership Sculptor Gmbh; Albert-Ludwigs-Universitaet Freiburg; Hadassah Medical Organization; Quantitative Genomic Medicine Laboratories Sl; Universita Della Svizzera Italiana; Research Fund of the Hadassah Medical Organization (R.A); Alia Therapeutics; Universitat de Barcelona; Ospedale San Raffaele Srl; Scienseed Sl; Deutsche Selbsthilfe Angeborene Immundefekte E. V.; Universita Degli Studi Di Trento; The Hebrew University of Jerusalem; Universite D'Aix Marseille; Onechain Immunotherapeutics S.L.; Fondazione Per L'Istituto Di Ricerca in Biomedicina; Olink Proteomics Ab; Universitaetsklinikum Freiburg; Centre National de la Recherche Scientifique CNRS; Fundacio Institut de Recerca Contra la Leucemia Josep Carreras; Universita Vita-Salute San Raffaele

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant